#1 Clinical Trials Search in Europe

Delandistrogene Moxeparvovec

Delandistrogene Moxeparvovec, also known as SRP-9001, is an investigational gene therapy being studied in clinical trials for the treatment of Duchenne Muscular Dystrophy (DMD). These trials aim to evaluate the safety, efficacy, and long-term effects of this potential treatment for patients with DMD, a rare genetic disorder characterized by progressive muscle weakness and degeneration.

Table of Contents

What is Duchenne Muscular Dystrophy?

Before diving into the details of delandistrogene moxeparvovec, it’s important to understand the condition it aims to treat. Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness[1]. It primarily affects boys and is caused by mutations in the dystrophin gene, which is responsible for producing a protein crucial for muscle strength and function.

What is Delandistrogene Moxeparvovec?

Delandistrogene moxeparvovec, also known by its product code SRP-9001, is an innovative gene therapy being developed to treat Duchenne Muscular Dystrophy[2]. It is classified as an advanced therapy medicinal product (ATMP) and specifically a gene therapy medicinal product (GTMP).

How Does Delandistrogene Moxeparvovec Work?

Delandistrogene moxeparvovec works by delivering a functional micro-dystrophin gene to muscle cells. Here’s a simplified explanation of the process:

  1. The therapy uses a modified virus called adeno-associated virus serotype rh74 (AAVrh74) as a vector to carry the genetic material.
  2. This vector contains a shortened version of the dystrophin gene, called micro-dystrophin.
  3. When administered, the vector enters muscle cells and delivers the micro-dystrophin gene.
  4. The cells then use this genetic information to produce the micro-dystrophin protein, which helps improve muscle function[2].

Clinical Trials and Research

Several clinical trials are underway to evaluate the safety and efficacy of delandistrogene moxeparvovec:

  • A long-term follow-up study (EXPEDITION) is assessing the safety and efficacy in patients who have previously received SRP-9001[1].
  • A study focusing on children under 4 years old with DMD is evaluating the safety and expression of SRP-9001[2].
  • The ENVISION trial is a Phase 3 study examining the therapy’s effects in both ambulatory (able to walk) and non-ambulatory DMD patients[3].

Safety and Efficacy

The clinical trials are closely monitoring the safety and effectiveness of delandistrogene moxeparvovec. Key points include:

  • Safety is being assessed through monitoring of adverse events, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)[3].
  • Efficacy is measured using various assessments, including:
    • Changes in muscle function tests like the North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL) test
    • Improvements in respiratory function (forced vital capacity and peak expiratory flow)
    • Quantity of micro-dystrophin protein expression in muscle tissue

Administration and Treatment

Delandistrogene moxeparvovec is administered as a single intravenous infusion. The dosage is measured in vector genomes (vg) per milliliter, with a maximum dose of 1.33 × 10^13 vg/mL[3]. It’s important to note that:

  • The treatment is designed as a one-time therapy.
  • Patients may need to undergo screening for antibodies against the AAVrh74 vector before treatment.
  • Some studies are exploring the use of immunosuppressive drugs like imlifidase to allow treatment in patients with pre-existing antibodies[4].

Future Prospects and Ongoing Research

While delandistrogene moxeparvovec shows promise, research is ongoing to fully understand its long-term effects and optimize its use. Future studies may focus on:

  • Expanding the eligible patient population, including different age groups and DMD mutations.
  • Combining gene therapy with other treatments to enhance outcomes.
  • Developing strategies to overcome immune responses to the therapy.

As research progresses, delandistrogene moxeparvovec represents a significant step forward in the treatment of Duchenne Muscular Dystrophy, offering hope to patients and families affected by this challenging condition.

Aspect Details
Drug Name Delandistrogene Moxeparvovec (SRP-9001)
Condition Treated Duchenne Muscular Dystrophy (DMD)
Type of Therapy Gene therapy
Administration One-time intravenous infusion
Trial Phases Phase 1, 2, and 3
Key Objectives Safety, efficacy, dystrophin expression, muscle function improvement
Patient Populations Ambulatory and non-ambulatory DMD patients, various age groups
Main Outcome Measures Dystrophin expression, functional assessments (PUL, NSAA), safety events
Follow-up Duration Up to 5 years in some studies

FAQ

  • What is Delandistrogene Moxeparvovec? Delandistrogene Moxeparvovec (SRP-9001) is an investigational gene therapy designed to treat Duchenne Muscular Dystrophy. It uses a modified virus to deliver a shortened version of the dystrophin gene to muscle cells, aiming to restore some dystrophin protein production.
  • Who is eligible for these clinical trials? Eligibility varies by trial, but generally includes patients with a confirmed diagnosis of DMD, specific age ranges, and genetic mutations in the DMD gene. Some trials focus on ambulatory patients, while others include non-ambulatory patients. Specific antibody levels and prior treatments may also affect eligibility.
  • What are the main objectives of these clinical trials? The main objectives include evaluating the safety of Delandistrogene Moxeparvovec, measuring changes in dystrophin protein expression, assessing improvements in muscle function and strength, and monitoring long-term effects of the treatment.
  • How is the treatment administered? Delandistrogene Moxeparvovec is administered as a one-time intravenous infusion. Some trials are exploring the use of imlifidase before administration to reduce pre-existing antibodies that might interfere with the treatment.
  • What are the potential risks and side effects? As with any investigational therapy, there may be unknown risks. The trials closely monitor for adverse events, including serious adverse events and events of special interest. Common side effects of gene therapies may include immune reactions, liver enzyme elevations, and temporary flu-like symptoms.

Ongoing Clinical Trials on Delandistrogene Moxeparvovec

  • Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy Spain

  • Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

    Not yet recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain Sweden

  • Study on the Safety and Efficacy of Delandistrogene Moxeparvovec and Imlifidase for Patients with Duchenne Muscular Dystrophy with Pre-existing Antibodies

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Duchenne Muscular Dystrophy (DMD): A genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin that helps keep muscle cells intact.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves delivering a modified version of the dystrophin gene to muscle cells.
  • Dystrophin: A protein that helps keep muscle cells intact. Its absence or dysfunction leads to the muscle degeneration seen in DMD.
  • Vector: A vehicle used to deliver genetic material into cells. In this case, a modified virus (AAV) is used to carry the dystrophin gene.
  • Adeno-associated virus (AAV): A small virus that infects humans but is not known to cause disease. Modified versions are often used in gene therapy to deliver genetic material to cells.
  • Western blot: A laboratory technique used to detect specific protein molecules from a complex mixture of proteins extracted from cells.
  • Immunofluorescence (IF): A technique used to visualize the location of specific proteins in cells or tissues using fluorescent antibodies.
  • North Star Ambulatory Assessment (NSAA): A standardized test used to measure functional motor abilities in ambulant children with DMD.
  • Performance of Upper Limb (PUL): A test designed to assess upper limb function in patients with DMD.
  • Forced Vital Capacity (FVC): A measure of lung function that represents the total amount of air exhaled forcefully after taking a deep breath.
  • Peak Expiratory Flow (PEF): The maximum rate of airflow achieved during a forceful exhalation, used to assess lung function.
  • Imlifidase: An enzyme being studied for its potential to reduce pre-existing antibodies that might interfere with gene therapy treatment.

References

  1. http://clinicaltrials.eu/trial/2023-505043-39-00
  2. http://clinicaltrials.eu/trial/2023-509901-57-00
  3. http://clinicaltrials.eu/trial/2024-512626-28-00
  4. http://clinicaltrials.eu/trial/2024-512624-11-00